Vertex Pharmaceuticals (VRTX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vertex Pharmaceuticals (VRTX)

VRTX 467.46

+1.4%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Casaubon who wrote (324)	10/4/1999 12:57:00 AM
From: Miljenko Zuanic	Read Replies (1) of 1169

In regards the any IMPDH inhibitor, as well 497, my concern is long term side effects profile, as results of prolonged immunosuppression lymphoma and skin carcinomas may develop. I will suggest (if you didn't) that you read full label for Ribavirin and Cellcept (PMA pro-drug). MPA interact with NAD-cofactor:IMP-substrate complex, non-nucleoside and noncompetitive inhibition. Similar inhibitory mechanisms have 497. The question is can this drug interfere with other mechanisms where NAD-cofactor is involved? I am not questioning 497 potency (as antiviral or immunosuppressive agent), but until more data on drug safety are known bit cautious approach will not hurt. Regardless that I have positive attitude toward 497. Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next